Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
$20.95
$1.44(1.16%)
At close: 4:00 PM EST
$20.95
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $138.81
Previous CloseN/A
Volume185.86K
Average Volume (3M)5.50M
Market Cap
$2.20B
Enterprise Value$2.33B
Total Cash (Recent Filing)$850.99M
Total Debt (Recent Filing)$1.26B
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Mar 03, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding104,787,186
10 Day Avg. Volume4,333,999
30 Day Avg. Volume5,501,936
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.57
Price to Sales (P/S)6.08
P/FCF Ratio-33.73
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.27
Enterprise Value/Ebitda-11.98
Forecast
1Y Price Target
$20.41Price Target Upside-2.58% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-4.84
Revenue Forecast (FY)$2.12B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceElevidys revenue of $132M beat consensus expectations of $95M.
Partnership And MilestonesThe collaboration agreement triggers a milestone payment of $200M to Arrowhead, expected to occur soon.
Product ApprovalThe FDA approval to initiate ENDEAVOR Cohort 8 is seen as a constructive step toward addressing safety concerns that have limited Elevidys access for nonambulatory patients.
Bears Say
Clinical Trial FailuresThe recent failure of the ESSENCE trial could put Vyondys 53 and Amondys 45 at risk of losing marketing authorization.
Market CompetitionElevidys faces continued growth pressure, with a dwindling and increasingly competitive patient pool, while Sarepta is forced to allocate non-revenue-generating doses to safety studies.
Regulatory ChallengesThe FDA's latest label action elevates Elevidys into a heightened-surveillance category, materially weakening the commercial narrative.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $10.41 and its highest was $138.81 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $2.20B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 93 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Nov 03, 2025. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$1.073.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Overvalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -1.35.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 104,787,186 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$1.8 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went down -33.742%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.41 (-2.58% Downside)
$20.41 (-2.58% Downside)
Blogger Sentiment
Neutral
SRPT Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 638.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.94%
12-Months-Change
Fundamentals
Return on Equity
-21.37%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is a biotechnology company focused on developing innovative genetic medicine therapies to treat rare diseases, particularly those related to muscular dystrophies. The company specializes in the development of RNA-targeted therapies, including exon-skipping technologies, to address the underlying causes of these genetic disorders. Its core products include the FDA-approved drug Eteplirsen, aimed at treating Duchenne muscular dystrophy (DMD), along with a robust pipeline of therapies in various stages of clinical development.
SRPT Company Deck
SRPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view, with significant achievements in revenue and study completions, alongside challenges such as the ESSENCE trial missing statistical significance and disruptions from paused shipments.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$20.41
▼(-2.58% Downside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
4.36% Insiders
14.15% Mutual Funds
4.67% Other Institutional Investors
52.33% Public Companies and Individual Investors